{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:10Z","timestamp":1792131010157,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11910-019-1014-z","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T14:02:42Z","timestamp":1574776962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Clinical Characteristics and Treatment of MOG-IgG\u2013Associated Optic Neuritis"],"prefix":"10.1007","volume":"19","author":[{"given":"Deena A.","family":"Tajfirouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tariq","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"12","key":"1014_CR1","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.4049\/jimmunol.139.12.4016","volume":"139","author":"HJ Schluesener","year":"1987","unstructured":"Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol. 1987;139(12):4016\u201321.","journal-title":"J Immunol"},{"issue":"1","key":"1014_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ana.20913","volume":"60","author":"L Steinman","year":"2006","unstructured":"Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006;60(1):12\u201321. https:\/\/doi.org\/10.1002\/ana.20913.","journal-title":"Ann Neurol"},{"issue":"2","key":"1014_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJMoa022328","volume":"349","author":"T Berger","year":"2003","unstructured":"Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349(2):139\u201345. https:\/\/doi.org\/10.1056\/NEJMoa022328.","journal-title":"N Engl J Med"},{"issue":"1","key":"1014_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"\u2022 Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm. 2018;15(1):134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2 This article provides recommendations regarding diagnosis and antibody testing based on the literature available as of 2018.","journal-title":"J Neuroinflamm"},{"key":"1014_CR5","doi-asserted-by":"publisher","first-page":"175628641876208","DOI":"10.1177\/1756286418762083","volume":"11","author":"MS Weber","year":"2018","unstructured":"Weber MS, Derfuss T, Metz I, Bruck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018;11:1756286418762083. https:\/\/doi.org\/10.1177\/1756286418762083.","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"1014_CR6","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"\u2022\u2022 Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128\u201338. https:\/\/doi.org\/10.1093\/brain\/awx276 This study discusses the clinical characteristics of MOGAD in a large cohort of patients from the UK, which includes an incidence cohort.","journal-title":"Brain"},{"key":"1014_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"\u2022 Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020 This study describes the clinical characteristics, radiological findings and outcomes of patients with optic neuritis from MOGAD in a large sample of patients.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1014_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/WNO.0000000000000779","volume":"39","author":"John J. Chen","year":"2019","unstructured":"Chen JJ, Fraser CL. Do myelin oligodendrocyte glycoprotein antibodies represent a distinct syndrome? J Neuroophthalmol. 2019. https:\/\/doi.org\/10.1097\/WNO.0000000000000779.","journal-title":"Journal of Neuro-Ophthalmology"},{"issue":"7","key":"1014_CR9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","volume":"263","author":"M Sepulveda","year":"2016","unstructured":"Sepulveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263(7):1349\u201360. https:\/\/doi.org\/10.1007\/s00415-016-8147-7.","journal-title":"J Neurol"},{"issue":"1","key":"1014_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"\u2022\u2022 Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. https:\/\/doi.org\/10.1186\/s12974-016-0718-0 This was one of the first large multicenter retrospective studies which reported the clinical presentation, radiological findings and long term outcomes of patients with MOGAD.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"1014_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"\u2022 Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127\u201337. https:\/\/doi.org\/10.1136\/jnnp-2017-316880 This study reports the clinical course and response to immunotherapy in patients with relapsing MOGAD.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1014_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83\u201397. https:\/\/doi.org\/10.1111\/bpa.12099.","journal-title":"Brain Pathol"},{"issue":"6","key":"1014_CR13","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1212\/NXI.0000000000000175","volume":"2","author":"F Di Pauli","year":"2015","unstructured":"Di Pauli F, Hoftberger R, Reindl M, Beer R, Rhomberg P, Schanda K, et al. Fulminant demyelinating encephalomyelitis: insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e175. https:\/\/doi.org\/10.1212\/NXI.0000000000000175.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"1014_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","volume":"2","author":"M Spadaro","year":"2015","unstructured":"Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol. 2015;2(3):295\u2013301. https:\/\/doi.org\/10.1002\/acn3.164.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"1014_CR15","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","volume":"22","author":"S Jarius","year":"2016","unstructured":"Jarius S, Metz I, Konig FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u2018pattern II multiple sclerosis\u2019 and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22(12):1541\u20139. https:\/\/doi.org\/10.1177\/1352458515622986.","journal-title":"Mult Scler"},{"key":"1014_CR16","doi-asserted-by":"publisher","unstructured":"de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2019;1352458519845112. https:\/\/doi.org\/10.1177\/1352458519845112.","DOI":"10.1177\/1352458519845112"},{"key":"1014_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.msard.2019.06.002","volume":"33","author":"MS Boesen","year":"2019","unstructured":"Boesen MS, Jensen PEH, Born AP, Magyari M, Nilsson AC, Hoei-Hansen C, et al. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 20082018: a nationwide, population-based cohort study. Mult Scler Relat Disord. 2019;33:162\u20137. https:\/\/doi.org\/10.1016\/j.msard.2019.06.002.","journal-title":"Mult Scler Relat Disord"},{"key":"1014_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","volume":"27","author":"M Etemadifar","year":"2019","unstructured":"Etemadifar M, Abbasi M, Salari M, Etemadifar F, Tavakoli H. Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome. Mult Scler Relat Disord. 2019;27:127\u201330. https:\/\/doi.org\/10.1016\/j.msard.2018.10.013.","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"1014_CR19","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","volume":"126","author":"Hitoshi Ishikawa","year":"2019","unstructured":"Ishikawa H, Kezuka T, Shikishima K, Yamagami A, Hiraoka M, Chuman H, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.042.","journal-title":"Ophthalmology"},{"issue":"21","key":"1014_CR20","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. OFSEP and NOMADMUS Study Group. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018;90(21):e1858\u2013e69. https:\/\/doi.org\/10.1212\/WNL.0000000000005560.","journal-title":"Neurology."},{"issue":"3","key":"1014_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000225","volume":"3","author":"M Sepulveda","year":"2016","unstructured":"Sepulveda M, Armangue T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e225. https:\/\/doi.org\/10.1212\/NXI.0000000000000225.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1014_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","volume":"265","author":"G Zhao","year":"2018","unstructured":"Zhao G, Chen Q, Huang Y, Li Z, Sun X, Lu P, et al. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. J Neurol. 2018;265(1):33\u201340. https:\/\/doi.org\/10.1007\/s00415-017-8651-4.","journal-title":"J Neurol"},{"issue":"10","key":"1014_CR23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","volume":"102","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Tan S, Chan TCY, Xu Q, Zhao J, Teng D, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102(10):1372\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311177.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1014_CR24","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00415-016-8155-7","volume":"263","author":"H Zhou","year":"2016","unstructured":"Zhou H, Zhao S, Yin D, Chen X, Xu Q, Chen T, et al. Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. J Neurol. 2016;263(7):1382\u20139. https:\/\/doi.org\/10.1007\/s00415-016-8155-7.","journal-title":"J Neurol"},{"key":"1014_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","volume":"305","author":"L Zhou","year":"2017","unstructured":"Zhou L, Huang Y, Li H, Fan J, Zhangbao J, Yu H, et al. MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J Neuroimmunol. 2017;305:19\u201328. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.01.007.","journal-title":"J Neuroimmunol"},{"key":"1014_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","volume":"381","author":"M Bouzar","year":"2017","unstructured":"Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, et al. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. J Neurol Sci. 2017;381:240\u20134. https:\/\/doi.org\/10.1016\/j.jns.2017.08.3254.","journal-title":"J Neurol Sci"},{"issue":"14","key":"1014_CR27","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1177\/1352458517734070","volume":"23","author":"K Soelberg","year":"2017","unstructured":"Soelberg K, Jarius S, Skejoe H, Engberg H, Mehlsen JJ, Nilsson AC, et al. A population-based prospective study of optic neuritis. Mult Scler. 2017;23(14):1893\u2013901. https:\/\/doi.org\/10.1177\/1352458517734070.","journal-title":"Mult Scler"},{"issue":"2","key":"1014_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89\u2013102. https:\/\/doi.org\/10.1038\/s41582-018-0112-x.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1014_CR29","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bjophthalmol-2018-313142","volume":"103","author":"Hongjuan Liu","year":"2018","unstructured":"Liu H, Zhou H, Wang J, Xu Q, Wei S. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. Br J Ophthalmol. 2018. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313142.","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"1014_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","volume":"15","author":"HJ Lee","year":"2018","unstructured":"Lee HJ, Kim B, Waters P, Woodhall M, Irani S, Ahn S, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation. 2018;15(1):302. https:\/\/doi.org\/10.1186\/s12974-018-1335-x.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"1014_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22(4):470\u201382. https:\/\/doi.org\/10.1177\/1352458515593406.","journal-title":"Mult Scler"},{"issue":"4","key":"1014_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","volume":"87","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87(4):446\u20138. https:\/\/doi.org\/10.1136\/jnnp-2014-310206.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1014_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"S Ramanathan","year":"2014","unstructured":"Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e40. https:\/\/doi.org\/10.1212\/NXI.0000000000000040.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1014_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jns.2018.11.029","volume":"396","author":"H Liu","year":"2019","unstructured":"Liu H, Zhou H, Wang J, Sun M, Teng D, Song H, et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. J Neurol Sci. 2019;396:225\u201331. https:\/\/doi.org\/10.1016\/j.jns.2018.11.029.","journal-title":"J Neurol Sci"},{"key":"1014_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-2094-7-52","volume":"7","author":"S Jarius","year":"2010","unstructured":"Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52. https:\/\/doi.org\/10.1186\/1742-2094-7-52.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"1014_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474\u201381. https:\/\/doi.org\/10.1212\/WNL.0000000000000101.","journal-title":"Neurology."},{"issue":"3","key":"1014_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5857.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1014_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617\u201327. https:\/\/doi.org\/10.1093\/brain\/aww350.","journal-title":"Brain."},{"issue":"3","key":"1014_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","volume":"76","author":"D Dubey","year":"2019","unstructured":"\u2022 Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4053 This study reports the clinical, radiological and prognostic features of MOGAD compared with myelitis with aquaporin-4 IgG and multiple sclerosis in a large retrospective study of patients.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1014_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00415-016-8360-4","volume":"264","author":"S Jarius","year":"2017","unstructured":"Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264(3):453\u201366. https:\/\/doi.org\/10.1007\/s00415-016-8360-4.","journal-title":"J Neurol"},{"issue":"6","key":"1014_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000163","volume":"2","author":"SM Kim","year":"2015","unstructured":"Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e163. https:\/\/doi.org\/10.1212\/NXI.0000000000000163.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1014_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, et al. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation. 2018;15(1):88. https:\/\/doi.org\/10.1186\/s12974-018-1108-6.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"1014_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O'Connor","year":"2007","unstructured":"O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13(2):211\u20137. https:\/\/doi.org\/10.1038\/nm1488.","journal-title":"Nat Med"},{"issue":"9","key":"1014_CR44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/jnnp-2019-320493","volume":"90","author":"A Petzold","year":"2019","unstructured":"Petzold A, Woodhall M, Khaleeli Z, Tobin WO, Pittock SJ, Weinshenker BG, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. J Neurol Neurosurg Psychiatry. 2019;90(9):1021\u20136. https:\/\/doi.org\/10.1136\/jnnp-2019-320493.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1014_CR45","doi-asserted-by":"publisher","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","volume":"92","author":"PJ Waters","year":"2019","unstructured":"\u2022 Waters PJ, Komorowski L, Woodhall M, Lederer S, Majed M, Fryer J, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019;92(11):e1250\u2013e5. https:\/\/doi.org\/10.1212\/WNL.0000000000007096 The authors compared MOG-IgG testing from 3different international centers, which showed good sensitivity and specificity for cell-based assays.","journal-title":"Neurology"},{"issue":"11","key":"1014_CR46","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS Lopez-Chiriboga","year":"2018","unstructured":"Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018;75(11):1355\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1814.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1014_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","volume":"88","author":"JW Hyun","year":"2017","unstructured":"Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811\u20137. https:\/\/doi.org\/10.1136\/jnnp-2017-315998.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1014_CR48","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","volume":"266","author":"A Cobo-Calvo","year":"2019","unstructured":"\u2022 Cobo-Calvo A, Sepulveda M, d'Indy H, Armangue T, Ruiz A, Maillart E, et al. Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol. 2019;266(4):806\u201315. https:\/\/doi.org\/10.1007\/s00415-018-9160-9 This study analyzes MOG-IgG titer levels at onset of disease, in correlation with the clinical phenotype and assesses the risk of future relapses.","journal-title":"J Neurol"},{"issue":"4","key":"1014_CR49","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572. https:\/\/doi.org\/10.1212\/NXI.0000000000000572.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"1014_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","volume":"136","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol. 2018;136(4):419\u201322. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.6757.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"1014_CR51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S, Merle H, Ferge JL, Mehdaoui H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346\u201351. https:\/\/doi.org\/10.1136\/jnnp-2017-316286.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1014_CR52","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archneurol.2011.34","volume":"68","author":"SM Magana","year":"2011","unstructured":"Magana SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011;68(7):870\u20138. https:\/\/doi.org\/10.1001\/archneurol.2011.34.","journal-title":"Arch Neurol"},{"issue":"7","key":"1014_CR53","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, Cabot F, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130(7):858\u201362. https:\/\/doi.org\/10.1001\/archophthalmol.2012.1126.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"1014_CR54","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"\u2022 Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018;75(4):478\u201387. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4601 This study evaluates treatment response in a large cohort of children with MOGAD.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1014_CR55","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","volume":"16","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sepulveda M, Rollot F, Armangue T, Ruiz A, Maillart E, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019;16(1):134. https:\/\/doi.org\/10.1186\/s12974-019-1525-1.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1014_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1\u201316. https:\/\/doi.org\/10.1007\/s00415-013-7169-7.","journal-title":"J Neurol"},{"key":"1014_CR57","doi-asserted-by":"crossref","unstructured":"Whittam D C-CA, Lopez-Chiriboga AS, Pardo S DJ, Brandt A, Berek K, et al. Treatment of MOG-IgG-associated demyelination with rituximab: a multinational study of 98 patients. Neurology. 2018;90(15).","DOI":"10.1212\/WNL.90.15_supplement.S13.003"},{"key":"1014_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2019.04.021","volume":"32","author":"E Tsantes","year":"2019","unstructured":"Tsantes E, Curti E, Siena E, Granella F. Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. Mult Scler Relat Disord. 2019;32:27\u20139. https:\/\/doi.org\/10.1016\/j.msard.2019.04.021.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"1014_CR59","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1900866.","journal-title":"N Engl J Med"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-019-1014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-019-1014-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-019-1014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T19:13:17Z","timestamp":1722107597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-019-1014-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1007\/s11910-019-1014-z","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"26 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Deena A. Tajfirouz, M. Tariq Bhatti, and John J. Chen each declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"100"}}